Homatropine Methylbromide

CHEMBL1200851 Phase 4 Zugelassen Small molecule
Half-Life
Bioavailability
Protein Binding
Molecular Weight
370.3 g/mol
LogP
Phase
4

A quaternary ammonium form of homatropine that does not cross the blood-brain barrier, used as an antispasmodic to reduce gastrointestinal cramping and as an antitussive adjunct. Its reduced central nervous system penetration means it lacks the sedative effects of tertiary anticholinergics. It is used primarily for its peripheral anticholinergic effects on smooth muscle and secretions.

Molekularmasse

370,3000 g/mol

TPSA

46,50 Ų

Wirkmechanismus

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Pharmacokinetics (PK)

Pharmacodynamics (PD)

Mechanismus

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

2D-Struktur

SVG PNG

Cite this structure


                        

Embed this structure


                        

SMILES

C[N+]1(C)[C@@H]2CC[C@H]1C[C@@H](OC(=O)C(O)c1ccccc1)C2.[Br-]

InChI

InChI=1S/C17H24NO3.BrH/c1-18(2)13-8-9-14(18)11-15(10-13)21-17(20)16(19)12-6-4-3-5-7-12;/h3-7,13-16,19H,8-11H2,1-2H3;1H/q+1;/p-1/t13-,14+,15+,16?;

Molecular Formula

C17H24BrNO3

HBD / HBA

1 / 4

Rotierbare Bindungen

4

Schwere Atome

22

No targets recorded

Target interaction data is not yet available for this drug.

No interactions recorded

Drug interaction data is not yet available for this compound.

No side effects recorded

Side effect data is not yet available for this drug.

Häufig gestellte Fragen

A quaternary ammonium form of homatropine that does not cross the blood-brain barrier, used as an antispasmodic to reduce gastrointestinal cramping and as an antitussive adjunct. Its reduced central nervous system penetration means it lacks the sedative effects of tertiary anticholinergics. It is used primarily for its peripheral anticholinergic effects on smooth muscle and secretions.

Competitively blocks muscarinic acetylcholine receptors, reducing parasympathetic nervous system activity. Effects include decreased secretions, bronchodilation, and relaxation of smooth muscle.

Yes, Homatropine Methylbromide is an approved drug. It has reached clinical phase 4. It is classified as a Small molecule.

{# References & Data Sources section for drug detail pages. Renders standard pharmacological database links plus the drug's data_sources field. #}

References & Data Sources

  • ChEMBL — European Bioinformatics Institute (EBI). CHEMBL1200851. Open-access bioactivity database.
  • PubChem — National Center for Biotechnology Information (NCBI). CID 6646. Chemical information database.

Data aggregated from publicly available pharmacological databases. Last updated 2026-03-04.

Medizinischer Haftungsausschluss

This content is for educational and informational purposes only. It is not a substitute for professional medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before making medication decisions.

Data sources: ChEMBL, PubChem, DailyMed.